<p><em>代表</em> <em>MindBio Therapeutics Corp. ( MBQIF )</em> <em>发布，可能包含付费广告。</em></p>
<p><em>纽约，2026 年 5 月 14 日（全球新闻稿）--</em> 通过 BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) 今天宣布其在 BioMedWire (BMW) 发布的社论中的位置，BMW 是动态品牌组合 @IBN（投资者品牌网络）中的 75 个以上品牌之一，专注于为私营和公共公司及投资社区提供金融新闻和内容分发的专业通讯平台。</p>
<p>要查看完整出版物 “实时醉酒检测平台瞄准不断扩大的数十亿美元医疗机会”，请访问：https://ibn.fm/uEoF8</p>
<p>数十年来，可靠识别药物和酒精影响一直是各行业面临的持续问题，从交通执法和职业安全到临床医学和公共卫生。传统工具如呼气测试仪、抽血和尿检由于其侵入性、缓慢的周转时间或无法实时捕捉影响，尤其是在涉及多种物质时，受到限制。随着物质使用模式的变化和醉酒的社会成本不断上升，开发更快、侵入性更小、可扩展的检测方法的压力正在加大。</p>
<p>MindBio Therapeutics Corp. ( MBQIF ) 正在采取一种独特的方法：利用人工智能（“AI”）和语音分析，通过简短的语音录音预测影响。通过将人声视为潜在生理和认知状态的窗口，MindBio 专注于构建一个能够实时检测多种物质醉酒的平台。这种方法填补了现有检测技术中的一个重要空白，并反映了向 AI 驱动的非侵入性诊断的更大趋势，具有重塑执法、雇主和健康系统识别和应对影响的潜力。</p>
<p><strong>关于 MindBio Therapeutics Corp. ( MBQIF )</strong></p>
<p>MindBio 是一家生物技术公司，正在商业化用于通过语音分析检测药物和酒精醉酒的 AI 预测技术。该 AI 预测模型使用超过 5000 万个数据点，仅通过人声就能以惊人的准确性预测酒精醉酒。该公司正在开发一个企业平台，包括集成定制硬件和软件的边缘 AI 自助终端，用于在包括矿业、航空、建筑和执法等多种企业环境中使用人声和 AI 检测药物和酒精醉酒。</p>
<p>欲了解更多信息，请访问公司网站 www.MindBioTherapeutics.com。</p>
<p><strong>投资者注意：</strong> 有关 <strong>MBQIF</strong> 的最新新闻和更新可在公司新闻室找到，网址为 https://ibn.fm/ <strong>MBQIF</strong></p>
<p><strong>关于 BioMedWire</strong></p>
<p>BioMedWire（“BMW”）是一个专注于生物技术（BioTech）、生物医学科学（BioMed）和生命科学领域最新发展的专业通讯平台。它是 <strong>动态品牌组合</strong>@ <strong>IBN</strong> 中的 75 个以上品牌之一，提供 <strong>：</strong> (1) 通过 InvestorWire 访问广泛的新闻解决方案网络，以高效有效地接触众多目标市场、人口统计和多样化行业； (2) 向 5000 多个媒体发布文章和社论； (3) 新闻稿增强以确保最大影响； (4) 通过 IBN 向数百万社交媒体关注者分发社交媒体； (5) 提供全方位定制的企业通讯解决方案。凭借广泛的覆盖面和经验丰富的记者和撰稿人团队，BMW 独特地为希望接触广泛投资者、影响者、消费者、记者和公众的私营和公共公司提供最佳服务。通过切入当今市场的信息过载，BMW 为其客户带来了无与伦比的认可和品牌知名度。</p>
<p>BMW 是突发新闻、深刻内容和可操作信息汇聚的地方。</p>
<p><strong>要接收来自 BioMedWire 的短信提醒，请发送 “Biotech” 至 888-902-4192（仅限美国手机）</strong></p>
<p>欲了解更多信息，请访问 https://www.BioMedWire.com</p>
<p><strong>免责声明</strong>：<strong>BioMedWire (BMW)</strong> 是上述文章和内容的来源。提及任何除被介绍的发行人以外的发行人仅旨在识别行业参与者，并不构成对任何发行人的认可，也不构成与被介绍的发行人的比较。BMW 在本发布中表达的评论、观点和意见仅代表 BMW。本文及内容的读者同意，他们不能也不会追究 BMW 对其读者或订阅者的任何投资决策的责任。BMW 是一家新闻传播和金融营销解决方案提供商，并非注册的经纪商/分析师/投资顾问，未持有任何投资许可证，且不得出售、提供出售或提供购买任何证券。</p>
<p>本文及与所述公司相关的内容代表作者的个人主观观点，随时可能更改，恕不另行通知。本文提供的信息来源于作者认为可靠的渠道。然而，作者并未独立验证或调查所有这些信息。作者、宝马或其任何关联公司均不保证任何此类信息的准确性或完整性。本文及内容不应被视为投资建议或对任何特定证券或行动方案的推荐；强烈建议读者与自己的投资顾问沟通，并在做出任何投资决策之前审查所述发行人向证券交易委员会提交的所有文件，并应了解与投资于所述发行人证券相关的风险，包括但不限于投资的全部损失。</p>
<p><strong>宝马不持有本公告中提到的任何公司的股份。</strong></p>
<p>本公告包含根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，并且这些前瞻性声明是根据《1995 年私人证券诉讼改革法》的安全港条款作出的。“前瞻性声明” 描述了未来的期望、计划、结果或策略，通常以 “可能”、“未来”、“计划” 或 “计划中”、“将” 或 “应该”、“预期”、“预料”、“草案”、“最终” 或 “预计” 等词开头。请注意，这些声明受到多种风险和不确定性的影响，可能导致未来的情况、事件或结果与前瞻性声明中预测的情况有重大差异，包括实际结果可能因各种因素与前瞻性声明中预测的结果有重大差异的风险，以及在公司提交给证券交易委员会的 10-K 或 10-KSB 表格的年度报告及其他文件中识别的其他风险。在评估本文中包含的前瞻性声明时，您应考虑这些因素，并且不应对这些声明过度依赖。本文中的前瞻性声明截至本公告日期作出，宝马不承担更新这些声明的义务。</p>
<p>请参阅 BioMedWire 网站上适用于宝马提供的所有内容的完整使用条款和免责声明：https://www.BioMedWire.com/Disclaimer</p>
<p>BioMedWire</p>
<p>德克萨斯州奥斯丁</p>
<p>www.BioMedWire.com</p>
<p>512.354.7000 办公室</p>
<p>Editor@BioMedWire.com</p>
<p>BioMedWire 由 IBN 提供支持</p>
<p>图片：https://www.globenewswire.com/newsroom/ti?nf=OTcyMDI0MSM3NjAzMjY4IzUwMDE2MjQ4MA==</p>
<p>图片：https://ml.globenewswire.com/media/YWI0ZmQ3NGMtZjhhNC00ZDZhLTllYjQtNDI2NzY0OTZkOGNiLTUwMDE2MjQ4MC0yMDI2LTA1LTE0LWVu/tiny/MindBio-Therapeutics-Corp-.png</p>
<p>图片：主要标志</p>
<p>来源：MindBio Therapeutics Corp. ( MBQIF )</p>

MBIO

<p>MindBio Therapeutics Corp.（CSE: MBIO）宣布了其利用人工智能和语音分析检测药物和酒精影响的创新方法。该方法旨在提供实时、非侵入性的影响检测，解决传统方法（如呼气测试和血液检测）的局限性。该公司正在开发一个平台，利用来自语音录音的超过 5000 万个数据点来准确预测醉酒水平。这项技术针对多个行业，包括采矿、航空和执法，并反映了医疗保健中日益增长的人工智能驱动的诊断趋势</p>

<p><em>Disseminated on behalf of</em> <em>MindBio Therapeutics Corp. ( MBQIF )</em> <em>and may include paid advertising.</em></p>
<div class="lb-trans"><p><em>代表</em> <em>MindBio Therapeutics Corp. ( MBQIF )</em> <em>发布，可能包含付费广告。</em></p>
</div><p><em>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) --</em> via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.</p>
<div class="lb-trans"><p><em>纽约，2026 年 5 月 14 日（全球新闻稿）--</em> 通过 BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) 今天宣布其在 BioMedWire (BMW) 发布的社论中的位置，BMW 是动态品牌组合 @IBN（投资者品牌网络）中的 75 个以上品牌之一，专注于为私营和公共公司及投资社区提供金融新闻和内容分发的专业通讯平台。</p>
</div><p>To view the full publication, “Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities,” please visit: https://ibn.fm/uEoF8</p>
<div class="lb-trans"><p>要查看完整出版物 “实时醉酒检测平台瞄准不断扩大的数十亿美元医疗机会”，请访问：https://ibn.fm/uEoF8</p>
</div><p>For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifying.</p>
<div class="lb-trans"><p>数十年来，可靠识别药物和酒精影响一直是各行业面临的持续问题，从交通执法和职业安全到临床医学和公共卫生。传统工具如呼气测试仪、抽血和尿检由于其侵入性、缓慢的周转时间或无法实时捕捉影响，尤其是在涉及多种物质时，受到限制。随着物质使用模式的变化和醉酒的社会成本不断上升，开发更快、侵入性更小、可扩展的检测方法的压力正在加大。</p>
</div><p>MindBio Therapeutics Corp. ( MBQIF ) is taking a distinctive approach: harnessing artificial intelligence (“AI”) and voice analysis to predict impairment from brief speech recordings. By treating the human voice as a window into underlying physiological and cognitive states, MindBio is focused on building a platform capable of detecting intoxication across a wide variety of substances in real time. This approach addresses a meaningful gap in existing detection technology and reflects a larger move toward AI-powered, noninvasive diagnostics with the potential to reshape how enforcement, employers and health systems identify and respond to impairment.</p>
<div class="lb-trans"><p>MindBio Therapeutics Corp. ( MBQIF ) 正在采取一种独特的方法：利用人工智能（“AI”）和语音分析，通过简短的语音录音预测影响。通过将人声视为潜在生理和认知状态的窗口，MindBio 专注于构建一个能够实时检测多种物质醉酒的平台。这种方法填补了现有检测技术中的一个重要空白，并反映了向 AI 驱动的非侵入性诊断的更大趋势，具有重塑执法、雇主和健康系统识别和应对影响的潜力。</p>
</div><p><strong>About MindBio Therapeutics Corp. ( MBQIF )</strong></p>
<div class="lb-trans"><p><strong>关于 MindBio Therapeutics Corp. ( MBQIF )</strong></p>
</div><p>MindBio is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.</p>
<div class="lb-trans"><p>MindBio 是一家生物技术公司，正在商业化用于通过语音分析检测药物和酒精醉酒的 AI 预测技术。该 AI 预测模型使用超过 5000 万个数据点，仅通过人声就能以惊人的准确性预测酒精醉酒。该公司正在开发一个企业平台，包括集成定制硬件和软件的边缘 AI 自助终端，用于在包括矿业、航空、建筑和执法等多种企业环境中使用人声和 AI 检测药物和酒精醉酒。</p>
</div><p>For more information, visit the company’s website at www.MindBioTherapeutics.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问公司网站 www.MindBioTherapeutics.com。</p>
</div><p><strong>NOTE TO INVESTORS:</strong> The latest news and updates relating to <strong>MBQIF</strong> are available in the company’s newsroom at https://ibn.fm/ <strong>MBQIF</strong></p>
<div class="lb-trans"><p><strong>投资者注意：</strong> 有关 <strong>MBQIF</strong> 的最新新闻和更新可在公司新闻室找到，网址为 https://ibn.fm/ <strong>MBQIF</strong></p>
</div><p><strong>About BioMedWire</strong></p>
<div class="lb-trans"><p><strong>关于 BioMedWire</strong></p>
</div><p>BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the <strong>Dynamic Brand Portfolio</strong>@ <strong>IBN</strong> that delivers <strong>:</strong> (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries <strong>;</strong> (2) article and editorial syndication to 5,000+ outlets <strong>;</strong> (3) press release enhancement to ensure maximum impact <strong>;</strong> (4) social media distribution via IBN to millions of social media followers <strong>;</strong> and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.</p>
<div class="lb-trans"><p>BioMedWire（“BMW”）是一个专注于生物技术（BioTech）、生物医学科学（BioMed）和生命科学领域最新发展的专业通讯平台。它是 <strong>动态品牌组合</strong>@ <strong>IBN</strong> 中的 75 个以上品牌之一，提供 <strong>：</strong> (1) 通过 InvestorWire 访问广泛的新闻解决方案网络，以高效有效地接触众多目标市场、人口统计和多样化行业； (2) 向 5000 多个媒体发布文章和社论； (3) 新闻稿增强以确保最大影响； (4) 通过 IBN 向数百万社交媒体关注者分发社交媒体； (5) 提供全方位定制的企业通讯解决方案。凭借广泛的覆盖面和经验丰富的记者和撰稿人团队，BMW 独特地为希望接触广泛投资者、影响者、消费者、记者和公众的私营和公共公司提供最佳服务。通过切入当今市场的信息过载，BMW 为其客户带来了无与伦比的认可和品牌知名度。</p>
</div><p>BMW is where breaking news, insightful content and actionable information converge.</p>
<div class="lb-trans"><p>BMW 是突发新闻、深刻内容和可操作信息汇聚的地方。</p>
</div><p><strong>To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)</strong></p>
<div class="lb-trans"><p><strong>要接收来自 BioMedWire 的短信提醒，请发送 “Biotech” 至 888-902-4192（仅限美国手机）</strong></p>
</div><p>For more information, please visit https://www.BioMedWire.com</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 https://www.BioMedWire.com</p>
</div><p><strong>DISCLAIMER</strong>: <strong>BioMedWire (BMW)</strong> is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.</p>
<div class="lb-trans"><p><strong>免责声明</strong>：<strong>BioMedWire (BMW)</strong> 是上述文章和内容的来源。提及任何除被介绍的发行人以外的发行人仅旨在识别行业参与者，并不构成对任何发行人的认可，也不构成与被介绍的发行人的比较。BMW 在本发布中表达的评论、观点和意见仅代表 BMW。本文及内容的读者同意，他们不能也不会追究 BMW 对其读者或订阅者的任何投资决策的责任。BMW 是一家新闻传播和金融营销解决方案提供商，并非注册的经纪商/分析师/投资顾问，未持有任何投资许可证，且不得出售、提供出售或提供购买任何证券。</p>
</div><p>The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.</p>
<div class="lb-trans"><p>本文及与所述公司相关的内容代表作者的个人主观观点，随时可能更改，恕不另行通知。本文提供的信息来源于作者认为可靠的渠道。然而，作者并未独立验证或调查所有这些信息。作者、宝马或其任何关联公司均不保证任何此类信息的准确性或完整性。本文及内容不应被视为投资建议或对任何特定证券或行动方案的推荐；强烈建议读者与自己的投资顾问沟通，并在做出任何投资决策之前审查所述发行人向证券交易委员会提交的所有文件，并应了解与投资于所述发行人证券相关的风险，包括但不限于投资的全部损失。</p>
</div><p><strong>BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.</strong></p>
<div class="lb-trans"><p><strong>宝马不持有本公告中提到的任何公司的股份。</strong></p>
</div><p>This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.</p>
<div class="lb-trans"><p>本公告包含根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，并且这些前瞻性声明是根据《1995 年私人证券诉讼改革法》的安全港条款作出的。“前瞻性声明” 描述了未来的期望、计划、结果或策略，通常以 “可能”、“未来”、“计划” 或 “计划中”、“将” 或 “应该”、“预期”、“预料”、“草案”、“最终” 或 “预计” 等词开头。请注意，这些声明受到多种风险和不确定性的影响，可能导致未来的情况、事件或结果与前瞻性声明中预测的情况有重大差异，包括实际结果可能因各种因素与前瞻性声明中预测的结果有重大差异的风险，以及在公司提交给证券交易委员会的 10-K 或 10-KSB 表格的年度报告及其他文件中识别的其他风险。在评估本文中包含的前瞻性声明时，您应考虑这些因素，并且不应对这些声明过度依赖。本文中的前瞻性声明截至本公告日期作出，宝马不承担更新这些声明的义务。</p>
</div><p>Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer</p>
<div class="lb-trans"><p>请参阅 BioMedWire 网站上适用于宝马提供的所有内容的完整使用条款和免责声明：https://www.BioMedWire.com/Disclaimer</p>
</div><p>BioMedWire</p>
<div class="lb-trans"><p>BioMedWire</p>
</div><p>Austin, Texas</p>
<div class="lb-trans"><p>德克萨斯州奥斯丁</p>
</div><p>www.BioMedWire.com</p>
<div class="lb-trans"><p>www.BioMedWire.com</p>
</div><p>512.354.7000 Office</p>
<div class="lb-trans"><p>512.354.7000 办公室</p>
</div><p>Editor@BioMedWire.com</p>
<div class="lb-trans"><p>Editor@BioMedWire.com</p>
</div><p>BioMedWire is powered by IBN</p>
<div class="lb-trans"><p>BioMedWire 由 IBN 提供支持</p>
</div><p>Image: https://www.globenewswire.com/newsroom/ti?nf=OTcyMDI0MSM3NjAzMjY4IzUwMDE2MjQ4MA==</p>
<div class="lb-trans"><p>图片：https://www.globenewswire.com/newsroom/ti?nf=OTcyMDI0MSM3NjAzMjY4IzUwMDE2MjQ4MA==</p>
</div><p>Image: https://ml.globenewswire.com/media/YWI0ZmQ3NGMtZjhhNC00ZDZhLTllYjQtNDI2NzY0OTZkOGNiLTUwMDE2MjQ4MC0yMDI2LTA1LTE0LWVu/tiny/MindBio-Therapeutics-Corp-.png</p>
<div class="lb-trans"><p>图片：https://ml.globenewswire.com/media/YWI0ZmQ3NGMtZjhhNC00ZDZhLTllYjQtNDI2NzY0OTZkOGNiLTUwMDE2MjQ4MC0yMDI2LTA1LTE0LWVu/tiny/MindBio-Therapeutics-Corp-.png</p>
</div><p>Image: Primary Logo</p>
<div class="lb-trans"><p>图片：主要标志</p>
</div><p>Source: MindBio Therapeutics Corp. ( MBQIF )</p>
<div class="lb-trans"><p>来源：MindBio Therapeutics Corp. ( MBQIF )</p>
</div>

MindBio Therapeutics Corp. (CSE: MBIO) 运用关键的人工智能和语音分析技术提供损伤解决方案